Inactive Instrument

All News InspireMD Inc Nyse

Equities

US45779A3095

End-of-day quote Nyse Other stock markets
- ^USD	-

14/05	Transcript : InspireMD, Inc., Q1 2024 Earnings Call, May 14, 2024
14/05	Earnings Flash (NSPR) INSPIREMD Posts Q1 Revenue $1.5M, vs. Street Est of $1.9M	MT

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million	01/07	AQ
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption Clinical Trial of CGuard at LINC 2024	29/05	AQ
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024	28/05	AQ
Transcript : InspireMD, Inc., Q1 2024 Earnings Call, May 14, 2024	14/05
Earnings Flash (NSPR) INSPIREMD Posts Q1 Revenue $1.5M, vs. Street Est of $1.9M	14/05	MT
InspireMD : Reports First Quarter 2024 Financial Results and Provides Business Update	14/05	PU
InspireMD, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th	07/05	AQ
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference	03/04	AQ
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024	26/03	AQ
Transcript : InspireMD, Inc., Q4 2023 Earnings Call, Mar 06, 2024	06/03
Earnings Flash (NSPR) INSPIREMD Posts Q4 Revenue $1.8M	06/03	MT
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update	06/03	AQ
InspireMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03	CI
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th	28/02	AQ
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System	12/02	AQ
InspireMD Gets CE Mark Recertification From the European Union	01/02	MT
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework	31/01	AQ
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America	03/01	AQ
InspireMD, Inc. Announces Appointment of Pete Ligotti as Executive Vice President and General Manager of North America	03/01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News InspireMD Inc Nyse

Equities

US45779A3095

All News

Filters